Neuroimmune-endocrine crosstalk in schizophrenia and mood disorders (Q36532151)

14 August 2017

1 reference

title

Neuroimmune-endocrine crosstalk in schizophrenia and mood disorders (English)

1 reference

14 August 2017

1 reference

1

Norbert Müller

1 reference

14 August 2017

Markus J Schwarz

2

1 reference

PubMed ID

16831116

14 August 2017

language of work or name

1 reference

1 July 2006

1 reference

Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders

14 August 2017

1 reference

14 August 2017

6

1 reference

14 August 2017

7

1 reference

14 August 2017

1017-1038

1 reference

Glutamate, dopamine, and schizophrenia: from pathophysiology to treatment

14 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

The current status of the dopamine hypothesis of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

Glutamate receptor dysfunction and schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

Prediction of the ability of clozapine to treat negative symptoms from plasma glycine and serine levels in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

First in vivo evidence of an NMDA receptor deficit in medication-free schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

Dizocilpine (MK-801) increases not only dopamine but also serotonin and norepinephrine transmissions in the nucleus accumbens as measured by microdialysis in freely moving rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

Systemic PCP treatment elevates brain extracellular 5-HT: a microdialysis study in awake rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

Plasma and platelet excitatory amino acids in psychiatric disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

Serum levels of excitatory amino acids, serine, glycine, histidine, threonine, taurine, alanine and arginine in treatment-resistant depression: modulation by treatment with antidepressants and prediction of clinical responsivity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

Subtype-specific alterations of gamma-aminobutyric acid and glutamate in patients with major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

The NR1 subunit of the glutamate/NMDA receptor in the superior temporal cortex in schizophrenia and affective disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

Decreased hippocampal NMDA, but not kainate or AMPA receptors in bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

Functional antagonists at the NMDA receptor complex exhibit antidepressant actions

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

Prolonged effect of an anesthetic dose of ketamine on behavioral despair

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

Possible use of amantadine in depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

Amantadine as augmentation therapy in the management of treatment-resistant depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

Small-dose ketamine improves the postoperative state of depressed patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

Antidepressant effect of ketamine during ECT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

Riluzole enhances glutamate uptake in rat astrocyte cultures

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

Riluzole augmentation for treatment-resistant depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

An open-label trial of riluzole in patients with treatment-resistant major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

An open-label trial of the glutamate-modulating agent riluzole in combination with lithium for the treatment of bipolar depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

Serologic evidence of prenatal influenza in the etiology of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

Maternal infections and subsequent psychosis among offspring.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

Maternal immune activation leads to behavioral and pharmacological changes in the adult offspring

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

Childhood meningitis, brain maturation and the risk of psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

Cytokine-induced sickness behavior: where do we stand?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

Cytokine-associated emotional and cognitive disturbances in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

Endotoxin-induced changes in food consumption in healthy volunteers are associated with TNF-alpha and IL-6 secretion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

Cytokine-specific central monoamine alterations induced by interleukin-1, -2 and -6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

T-helper-1 and T-helper-2 responses in psychiatric disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

IDO and interferon-alpha-induced depressive symptoms: a shift in hypothesis from tryptophan depletion to neurotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

The HPA and immune axes in stress: the involvement of the serotonergic system

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

Investigations of cytokine production in whole blood cultures of paranoid and residual schizophrenic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

Cellular and humoral immune system in schizophrenia: a conceptual re-evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

Plasma levels of cytokines and soluble cytokine receptors in psychiatric patients upon hospital admission: effects of confounding factors and diagnosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

Cytokines production in chronic schizophrenia patients with or without paranoid behaviour.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

Is there an immunologic basis for schizophrenia?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

Immune correlates of depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

Depression and immunity: a meta-analytic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

Increased neopterin and interferon-gamma secretion and lower availability of L-tryptophan in major depression: further evidence for an immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

Immune markers in fibromyalgia: comparison with major depressed patients and normal volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

Cytokines and major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

Possible association between -G308A tumour necrosis factor-alpha gene polymorphism and major depressive disorder in the Korean population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

Analysis of IL-1alpha, IL-1beta, and IL-1RA [correction of IL-RA] polymorphisms in dysthymia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

Interleukin-1beta (IL-1beta) gene and increased risk for the depressive symptom-dimension in schizophrenia spectrum disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

Th1, Th2, and Th3 cytokine alterations in major depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

Correlation between sICAM-1 and depressive symptoms during adjuvant treatment of melanoma with interferon-alpha.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

Soluble intercellular adhesion molecule-1 in cerebrospinal fluid: an indicator for the inflammatory impairment of the blood-cerebrospinal fluid barrier.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

Increased soluble interleukin-2 receptor concentrations in suicide attempters.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

Immunologic variables in acute mania of bipolar disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

Cytokine production in bipolar affective disorder patients under lithium treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

Cytokine profiles in bipolar affective disorder: focus on acutely ill patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

Post-influenzal psychiatric disorder in adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

Depression as a cerebral manifestation of scleroderma: immunological findings in serum and cerebrospinal fluid

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

Investigation of the effects and aftereffects of naturally occurring upper respiratory tract illnesses on mood and performance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

Cytokines, "depression due to a general medical condition," and antidepressant drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

Depression in medical illness: the role of the immune system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

Increased depressive ratings in patients with hepatitis C receiving interferon-alpha-based immunotherapy are related to interferon-alpha-induced changes in the serotonergic system

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

Suicidal ideation during interferon-alpha2b and ribavirin treatment of patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

Association between decreased serum tryptophan concentrations and depressive symptoms in cancer patients undergoing cytokine therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

Interferon-alpha-induced changes in tryptophan metabolism. relationship to depression and paroxetine treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

The relationship between depression and interferon beta-1a therapy in patients with multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

Interferon-beta affects the tryptophan metabolism in multiple sclerosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

Depressive and anxiety symptoms in the early puerperium are related to increased degradation of tryptophan into kynurenine, a phenomenon which is related to immune activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

Pregnancy in patients with rheumatic disease: anti-inflammatory cytokines increase in pregnancy and decrease post partum

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

The pattern of mental change and body weight change in the first post-partum week

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

Measurement of tryptophan, kynurenine and neopterin in women with and without postpartum blues

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

On the clinical relevance of clozapine-triggered release of cytokines and soluble cytokine-receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

Increased serum IL-6 and IL-1 receptor antagonist concentrations in major depression and treatment resistant depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

Effects of zimeldine and its metabolites, clomipramine, imipramine and maprotiline in experimental allergic neuritis in Lewis rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

Effects of antidepressants on the production of cytokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

IL-6 levels decrease with SSRI treatment in patients with major depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

Cytokine-induced changes in mood and behaviour: implications for 'depression due to a general medical condition', immunotherapy and antidepressive treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

Sleep associated regulation of T helper 1/T helper 2 cytokine balance in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

Interleukine-6 serum levels correlate with response to antidepressant sleep deprivation and sleep phase advance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

Effects of exercise training on older patients with major depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

Benefits of exercise for the treatment of depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

Muscle-derived interleukin-6--a possible link between skeletal muscle, adipose tissue, liver, and brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

Physical activity and plasma interleukin-6 in humans--effect of intensity of exercise.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

Pro- and anti-inflammatory cytokine balance in strenuous exercise in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

The anti-inflammatory effect of exercise

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

Exercise normalises overexpression of TNF-alpha in knockout mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

Interleukin-6 release from the human brain during prolonged exercise.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

Interleukin-6 expression and regulation in astrocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

Boxing and running lead to a rise in serum levels of S-100B protein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

Manipulation of brain kynurenines: glial targets, neuronal effects, and clinical opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

A glycine site associated with N-methyl-D-aspartic acid receptors: characterization and identification of a new class of antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

Tolerance, DCs and tryptophan: much ado about IDO

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

Expression of the kynurenine pathway enzyme tryptophan 2,3-dioxygenase is increased in the frontal cortex of individuals with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

Regulation of T-cell responses by CNS antigen-presenting cells: different roles for microglia and astrocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

Quinolinic acid selectively induces apoptosis of human astrocytes: potential role in AIDS dementia complex.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

Tryptophan catabolism and T-cell tolerance: immunosuppression by starvation?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

Inhibition of T cell proliferation by macrophage tryptophan catabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

A two-step induction of indoleamine 2,3 dioxygenase (IDO) activity during dendritic-cell maturation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

The role of IFN-gamma and TNF-alpha-responsive regulatory elements in the synergistic induction of indoleamine dioxygenase

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

Interferons and indoleamine 2,3-dioxygenase: role in antimicrobial and antitumor effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

Suicide attempts and impulse control disorder are related to low cerebrospinal fluid 5-HIAA in mentally disordered violent offenders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

Serum S100B is increased during early treatment with antipsychotics and in deficit schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

Increased serum S100B in elderly, chronic schizophrenic patients: negative correlation with deficit symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

Glial cell dysfunction in schizophrenia indicated by increased S100B in the CSF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

Evidence for activation of microglia in patients with psychiatric illnesses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

Glial reduction in the subgenual prefrontal cortex in mood disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

Morphometric evidence for neuronal and glial prefrontal cell pathology in major depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

Reductions in neuronal and glial density characterize the dorsolateral prefrontal cortex in bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

Depression: what we can learn from postmortem studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

Disease-specific alterations in frontal cortex brain proteins in schizophrenia, bipolar disorder, and major depressive disorder. The Stanley Neuropathology Consortium

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

Age-dependent reductions in the level of glial fibrillary acidic protein in the prefrontal cortex in major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

Glial fibrillary acidic protein in late life major depressive disorder: an immunocytochemical study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

Altered cortical glutamatergic and GABAergic signal transmission with glial involvement in depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

Regulation of glutamate transporters in health and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

Fast removal of synaptic glutamate by postsynaptic transporters.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

On the production and disposition of quinolinic acid in rat brain and liver slices.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

A beta 1-42 induces production of quinolinic acid by human macrophages and microglia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

Upregulation of the initiating step of the kynurenine pathway in postmortem anterior cingulate cortex from individuals with schizophrenia and bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

Quinolinic acid and kynurenine pathway metabolism in inflammatory and non-inflammatory neurological disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

Quinolinic acid in cerebrospinal fluid and serum in HIV-1 infection: relationship to clinical and neurological status

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

An evaluation of the role of extracellular amino acids in the delayed neurodegeneration induced by quinolinic acid in the rat striatum.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

NMDA and non-NMDA receptor-mediated excitotoxicity are potentiated in cultured striatal neurons by prior chronic depolarization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

Cytokine–serotonin interaction through IDO: a neurodegeneration hypothesis of depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

Expression of the kynurenine enzymes in macrophages and microglial cells: regulation by immune modulators

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

Synthesis and release of neurotoxic kynurenine metabolites by human monocyte-derived macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

Increased arachidonic acid induced platelet chemiluminescence indicates cyclooxygenase overactivity in schizophrenic subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

Neuronal expression of cyclooxygenase-2, a pro-inflammatory protein, in the hippocampus of patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

Triptolide inhibits COX-2 expression via NF-kappa B pathway in astrocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

COX-2, CB2 and P2X7-immunoreactivities are increased in activated microglial cells/macrophages of multiple sclerosis and amyotrophic lateral sclerosis spinal cord

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

Prostaglandin E(2) upregulates cyclooxygenase-2 expression in lipopolysaccharide-stimulated RAW 264.7 macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

The inflammatory response system and the availability of plasma tryptophan in patients with primary sleep disorders and major depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

Immunoregulators in the nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

Discovering endophenotypes for major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

Depression and cortisol responses to psychological stress: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

Cytokines: abnormalities in major depression and implications for pharmacological treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

Role of interleukin-1 beta in impairment of contextual fear conditioning caused by social isolation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

Relationship between cyclooxygenase-2 and nitric oxide synthase-2 in rat cortex after stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

Immunoregulatory feedback between interleukin-1 and glucocorticoid hormones

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

Corticotropin-releasing factor-producing neurons in the rat activated by interleukin-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

Exposure to excess glucocorticoids alters dendritic morphology of adult hippocampal pyramidal neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

Corticosterone acutely prolonged N-methyl-d-aspartate receptor-mediated Ca2+ elevation in cultured rat hippocampal neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

Stress-induced elevation of glucocorticoids increases microglia proliferation through NMDA receptor activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

Repeated prenatal corticosteroids reduce glial fibrillary acidic protein in the ovine central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

Prostaglandin E(2) increases bovine leukemia virus tax and pol mRNA levels via cyclooxygenase 2: regulation by interleukin-2, interleukin-10, and bovine leukemia virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

Prostaglandins as modulators of immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

Aberrant prostaglandin synthase 2 expression defines an antigen-presenting cell defect for insulin-dependent diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

Prostaglandin-mediated control of rat brain kynurenic acid synthesis--opposite actions by COX-1 and COX-2 isoforms

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

Nonsteroidal anti-inflammatory drugs and severe psychiatric side effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

Non-steroidal anti-inflammatory drugs with adverse psychiatric reactions: five case reports

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

Clinical effects of COX-2 inhibitors on cognition in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

COX-2 inhibition as a treatment approach in schizophrenia: immunological considerations and clinical effects of celecoxib add-on therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

Celecoxib augmentation of continuously ill patients with schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

Inhibition of COX-2 reduces the age-dependent increase of hippocampal inflammatory markers, corticosterone secretion, and behavioral impairments in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

Inhibition of COX-2 by celecoxib enhances glucocorticoid receptor function

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

Effect of rofecoxib on nociception and the serotonin system in the rat brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

Inhibitors of cyclooxygenase-2, but not cyclooxygenase-1 provide structural and functional protection against quinolinic acid-induced neurodegeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

Improved control of osteoarthritis pain and self-reported health status in non-responders to celecoxib switched to rofecoxib: results of PAVIA, an open-label post-marketing survey in Spain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

Coxibs and cardiovascular side-effects: from light to shadow.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

Celecoxib and cardiovascular risks

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

Cardiovascular hazard and non-steroidal anti-inflammatory drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

Plasma glycine and serine levels in schizophrenia compared to normal controls and major depression: relation to negative symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

Increased plasma concentrations of interleukin-6, soluble interleukin-6, soluble interleukin-2 and transferrin receptor in major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

Plasma-soluble interleukin-2 and transferrin receptor in schizoprenia and major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

Increased serum tumor necrosis factor alpha concentrations in major depression and multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

Relationships between interleukin-6 activity, acute phase proteins, and function of the hypothalamic-pituitary-adrenal axis in severe depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

Indicators of immune activation in major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

Interleukin-2 and interleukin-6 in schizophrenia and mania: Effects of neuroleptics and mood stabilizers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

Negative Immunoregulatory Effects of Antidepressants Inhibition of Interferon-γ and Stimulation of Interleukin-10 Secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

Exposure to Prenatal and Childhood Infections and the Risk of Schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

Elevation in Late-Life Depression of Intercellular Adhesion Molecule-1 Expression in the Dorsolateral Prefrontal Cortex

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

Childhood central nervous system infections and risk for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

Cerebrospinal fluid amines and higher-lethality suicide attempts in depressed inpatients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.7.1017

10.1586/14737175.6.7.1017

21 January 2018

Identifiers

DOI

1 reference

14 August 2017

1 reference

PubMed ID

16831116